Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1.82% is 99% above its 4-year average of -166.25%, near the high end of its 4-year range (-14415.45%–15.17%).
175.26% below its 12-month average of 2.42%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 13.08%.
EBITDA MARGIN
-1.82%
EBITDA MARGIN AVG TTM
2.42%
EBITDA MARGIN AVG 3Y
-39.51%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-175.26%
CURRENT VS 3Y AVG
+95.39%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Arcutis Biotherapeutics, Inc.
Market Cap
$3.04B
EBITDA Margin
-1.82%
TTM Avg
2.42%
3Y Avg
-39.51%
5Y Avg
N/A
Market Cap
$3.11B
EBITDA Margin
-54.45%
TTM Avg
-179.51%
3Y Avg
-231.98%
5Y Avg
-287.87%
Market Cap
$3.01B
EBITDA Margin
-359.19%
TTM Avg
-174.35%
3Y Avg
-417.41%
5Y Avg
-1450.57%
Market Cap
$2.83B
EBITDA Margin
89.92%
TTM Avg
49.57%
3Y Avg
44.47%
5Y Avg
4968.54%
Market Cap
$2.83B
EBITDA Margin
22.42%
TTM Avg
17.70%
3Y Avg
-0.76%
5Y Avg
-37.34%
Market Cap
$3.40B
EBITDA Margin
10.88%
TTM Avg
18.32%
3Y Avg
-3.89%
5Y Avg
-19.05%
Market Cap
$2.74B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | $3.04B | -1.82% | 2.42% | -39.51% | N/A |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.11B | N/A | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.11B | -54.45% | -179.51% | -231.98% | -287.87% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.01B | -359.19% | -174.35% | -417.41% | -1450.57% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.83B | 89.92% | 49.57% | 44.47% | 4968.54% |
| TransMedics Group, Inc. (TMDX)vs › | $2.83B | 22.42% | 17.70% | -0.76% | -37.34% |
| AtriCure, Inc. (ATRC)vs › | $2.81B | 3.20% | -0.69% | -3.43% | -1.09% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.40B | 10.88% | 18.32% | -3.89% | -19.05% |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.74B | N/A | N/A | N/A | N/A |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.71B | 11.88% | 11.88% | 7.44% | -2.29% |
Gross Margin
91.1%
EBITDA Margin
-1.8%
Operating Margin
-3.3%
Net Margin
6.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 13.08% |
| 2026-03-31 | -8.09% |
| 2025-12-31 | 15.17% |
| 2025-09-30 | 9.16% |
| 2025-06-30 | -17.24% |
| 2025-03-31 | -32.50% |
| 2024-12-31 | -10.05% |
| 2024-09-30 | -84.09% |
| 2024-06-30 | -161.14% |
| 2024-03-31 | -63.07% |
| 2023-12-31 | -449.39% |
| 2023-09-30 | -95.82% |
| 2023-06-30 | -1277.24% |
| 2023-03-31 | -2729.31% |
| 2022-12-31 | -2299.12% |
| 2022-09-30 | -14415.45% |
